Small Molecules

15 Jan 2020 Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase
15 Jan 2020 Cerevel Therapeutics Initiates Phase 3 Program of Tavapadon for the Treatment of Parkinson’s Disease
13 Jan 2020 Acasti Pharma Reports Topline Results for TRILOGY 1 Phase 3 Trial of CaPre
13 Jan 2020 Cyclerion announces IW-6463 phase 1 healthy volunteer study results that support further development for neurodegenerative diseases
13 Jan 2020 Spero Reports Preliminary Findings from Phase 1 Clinical Trial of SPR206 and Plans to Advance Program with Alliance Partners Everest Medicines and the Department of Defense
13 Jan 2020 Update on Phase III STRENGTH trial for Epanova in mixed dyslipidaemia
13 Jan 2020 LYNPARZA® (olaparib) regulatory submission granted priority review in US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
12 Jan 2020 Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor
12 Jan 2020 Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study
12 Jan 2020 ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
12 Jan 2020 Terns Pharmaceuticals Presents Results From An Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH
10 Jan 2020 Blueprint Medicines Announces FDA Approval of AYVAKIT™ (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
09 Jan 2020 Retrotope Expands its Drug Pipeline with the First Dosing of RT001 in patients with Friedreich’s ataxia (FA)
09 Jan 2020 Applied Therapeutics Announces Positive Topline Results of Pivotal Phase 2 ACTION-Galactosemia Study of AT-007 in Galactosemia Patients
09 Jan 2020 Blueprint Medicines Announces Top-line Data for Pralsetinib and Initiates Rolling NDA Submission to FDA for the Treatment of Patients with RET Fusion-Positive Non-Small Cell Lung Cancer
09 Jan 2020 AMO Pharma Announces Initiation of Planned Pivotal Clinical Trial for Myotonic Dystrophy Following $35m Fund Raise
09 Jan 2020 OrphoMed Initiates U.S. Phase 2 Adaptive Design Study of ORP-101 for Treatment of IBS-D
08 Jan 2020 PellePharm Initiates Phase 2 Clinical Trial of Patidegib Topical Gel for People With High Frequency Basal Cell Carcinoma
08 Jan 2020 Axcella Announces Positive Interim Findings from Ongoing Clinical Study of AXA1125/AXA1957 in Subjects with NAFLD and Expected 2020 Milestones
08 Jan 2020 Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma
07 Jan 2020 Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274
07 Jan 2020 AlzeCure Pharma Conducts Strategic Inlicensing of Clinical Phase Drug Candidate for Neuropathic Pain
07 Jan 2020 InxMed Announces Clinical Collaboration with MSD to Evaluate IN10018 in Combination with Pembrolizumab
07 Jan 2020 Lyra Therapeutics Announces FDA Clearance of Investigational New Drug Application for a Phase 2 Clinical Trial of LYR-210 for Chronic Rhinosinusitis
07 Jan 2020 Oxurion NV Reports Positive Topline Data from Phase 1 study evaluating THR-687 for treatment of DME

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up